Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Centre Hospitalier Universitaire De Nantes

Centre National De La Recherche Scientifique

Leland Stanford Junior University

Ose Immunotherapeutics

Chu Nantes

Centre National De La Recherche Scientifique-cnrs

Nantes Université

Inserm

Sophie Brouard

Richard Danger

Antoine Magnan

Pierre-Joseph Royer

Jean-Paul Soulillou

Magali Giral

Nicolas Poirier

Bernard Vanhove

Caroline Mary

Minnie M Sarwal

Elaine S Mansfield

Le Hoa Mai

Gérard Ramstein

Maxim Durand

Carole Brosseau

Michelle Yap

Jean-Paul Soulilou

Minnie Sarwal

Nicolas Degauque

Yohann Foucher

Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.

Methods and compositions for predicting chronic lung allograft dysfunction

The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9B cells in a blood sample of the subject, b) comparing the level of CD9B cells measured at step a) with one or more reference values of the level of CD9B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).

CD24CD38transitional B cells and CD9 as new biomarker of long-term human lung allograft survival

The present invention relates to a method for discriminating an operationally tolerant (TOL) subject from a non-operationally tolerant (STA) subject, comprising the following steps: 

Methods for discriminating a tolerant subject

The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia/lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.

The invention relates to a method for predicting graft alterations in a transplanted patient, comprising a step of determining the expression levels of bactericidal/permeability-increasing protein (BPI), chemokine (C motif) ligand 1 (XCL1) and thioredoxin domain containing 3 (TXNDC3) genes in a biological sample obtained from said transplanted patient.

Methods for predicting graft alterations

The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.

Antibodies directed against the alpha chain of IL7 receptor&#x2014;their use for the preparation of drug candidates

Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood sample, is assayed to obtain an expression evaluation for the at least one gene. The obtained expression evaluation is then employed to determine whether the subject has a graft tolerant phenotype. Also provides are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.

Methods and compositions for determining a graft tolerant phenotype in a subject

Growing community of inventors

Sucé-sur-Erdre, France

Sophie Brouard